Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
A phase 2 trial of Vorolanib and Sintilimab in Renal cell carcinoma, run by Hao Zeng, not yet recruiting.
Overview
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy is a phase 2 interventional study registered as NCT06523049 by Hao Zeng, with 67 participants planned, started 2024-08 and due to reach its primary completion in 2026-07. Interventions recorded: Vorolanib Tablets, Sintilimab Injection. Conditions recorded: Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy.
Linked to the drug Vorolanib because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialVorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
Shares Vorolanib, Renal cell carcinoma and the tag pipeline.
- TrialVorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Shares Vorolanib and the tag pipeline.
- TrialAssessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Shares Sintilimab and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Renal cell carcinoma and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialStudy of ST-1898 in Advanced Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialAB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Shares Renal cell carcinoma and the tag pipeline.
- TrialAn Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Shares Renal cell carcinoma and the tag pipeline.